Buy Sanofi ADR stock in 5 easy steps, view past price performance and learn what’s ahead for the company.
Sanofi ADR is a drug manufacturers - general business based in the US. Sanofi ADR shares (SNY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $51.78 – . Sanofi ADR employs 82,878 staff and has a trailing 12-month revenue of around $45.9 billion.
Become a Finder member, open a SoFi Active Invest account and make a first deposit of $1,000 or more to receive a $150 gift card. Offer ends November 30, 2025.
T&Cs and limits apply.
Trade stocks, options, ETFs, mutual funds, alternative asset funds
$0 commission on stocks, ETFs and options with no options contract fees
Get up to $1,000 in stock when you open and fund a new account within 30 days
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Sanofi ADR stock price (NASDAQ: SNY)
Use our graph to track the performance of SNY stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Sanofi ADR stock undervalued or overvalued?
Valuing Sanofi ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sanofi ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sanofi ADR's P/E ratio
Sanofi ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Sanofi ADR shares trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Sanofi ADR's PEG ratio
Sanofi ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7938. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sanofi ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Sanofi ADR's EBITDA
Sanofi ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12.3 billion.
The EBITDA is a measure of a Sanofi ADR's overall financial performance and is widely used to measure a its profitability.
Sanofi ADR financials
Revenue TTM
$45.9 billion
Operating margin TTM
28.73%
Gross profit TTM
$33.1 billion
Return on assets TTM
4.61%
Return on equity TTM
8.84%
Profit margin
19.84%
Book value
$60.15
Market Capitalization
$127.3 billion
TTM: trailing 12 months
Sanofi ADR share dividends
Dividend payout ratio: 51.46% of net profits
Recently Sanofi ADR has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sanofi ADR shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Sanofi ADR's case, that would currently equate to about $0 per share.
Sanofi ADR's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Sanofi ADR's most recent dividend payout was on 11 June 2025. The latest dividend was paid out to all shareholders who bought their shares by 8 May 2025 (the "ex-dividend date").
Have Sanofi ADR's shares ever split?
Sanofi ADR's shares were
split on a 5:1 basis on 29 September 2013
. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Sanofi ADR shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Sanofi ADR shares which in turn could have impacted Sanofi ADR's share price.
Sanofi ADR share price volatility
Over the last 12 months, Sanofi ADR's shares have ranged in value from as little as $43.8566 up to $57.5689. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sanofi ADR's is 0.371. This would suggest that Sanofi ADR's shares are less volatile than average (for this exchange).
Sanofi ADR overview
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc.
Frequently asked questions
What percentage of Sanofi ADR is owned by insiders or institutions? Currently 0.003% of Sanofi ADR shares are held by insiders and 9.861% by institutions.How many people work for Sanofi ADR? Latest data suggests 82,878 work at Sanofi ADR.When does the fiscal year end for Sanofi ADR? Sanofi ADR's fiscal year ends in December.Where is Sanofi ADR based? Sanofi ADR's address is: 46, avenue de la Grande Armée, Paris, France, 75017What is Sanofi ADR's ISIN number? Sanofi ADR's international securities identification number is: US80105N1054What is Sanofi ADR's CUSIP number? Sanofi ADR's Committee on Uniform Securities Identification Procedures number is: 80105N204
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
